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The metabolism of 9-( 1,3-dihydroxy-Z-propoxy- 
methy1)guanine (DHPG), one of the most promising 
new anti-herpes virus compounds, in HeLa cells in- 
fected  with  herpes  simplex  virus  type 1 was compared 
with that in the uninfected HeLa cells. In the virus- 
infected cells,  the uptake of DHPG was enhanced and 
the major metabolites were found to be the mono-, di-, 
and triphosphate derivatives.  The formation of these 
metabolites was dependent on the extracellular con- 
centration of DHPG (0.5 to 5.0 "). Virus-induced 
thymidine kinase  was capable of phosphorylating 
DHPG to its monophosphate which could be further 
phosphorylated to  the  di- and triphosphate derivatives 
by the host cellular enzymes. Incorporation of the 
DHPG into DNA was observed in virus-infected  cells. 
In contrast with 9-(2-hydroxyethoxymethyl)guanine, 
DHPG seemed not to serve  as a chain terminator, but 
to be incorporated internally  into DNA strands. 
DHPG,' a newly synthesized guanosine  analog,  was  found 
to have potent activity against HSV (1-3), varicella-zoster 
virus (I), cytomegalovirus (2, 3), and  Epstein-Barr  virus (3). 
DHPG  is more potent  and  the  spectrum of susceptible  viruses 
to  the  compound is broader  than  that  to acyclovir. Further- 
more, HSV  mutants, which are  resistant to acyclovir because 
of altered thymidine kinase or DNA polymerase, were as 
sensitive to DHPG as the parental HSV (3). This unique 
spectrum of activity suggests the  potential use of DHPG  in 
the clinic  for the  treatment of herpesvirus infection. In  order 
to have  a better  understanding of the  mechanism of action of 
DHPG, it is important to explore its metabolism in virus- 
infected cells. This  paper  presents evidence of phosphoryla- 
tion of DHPG,  leading  to  the  formation of DHPGTP,  and of 
incorporation of the nucleoside analog  into DNA. 
MATERIALS  AND  METHODS 
Chemicals and Enzymes-DHPG, DHPGMP,  and  [3H]DHPG (16 
Ci/mmol) were donated by Syntex (U.S.A.), Inc., Palo Alto, CA. 
Other nucleosides, nucleotides, and dithiothreitol were purchased 
from Sigma. Proteinase K and micrococcal nuclease were obtained 
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The abbreviations used are: DHPG, 9-(1,3-dihydroxypropoxy- 
methy1)guanine; DHPGMP,  DHPGDP,  DHPGTP, 9-(1,3-dihydrox- 
ypropoxymethy1)guanine mono-, di-,  and  triphosphate, respectively; 
HSV-1, herpes simplex virus type 1; acyclovir, g-(Z-hydroxyethoxy- 
methy1)guanine; HPLC, high performance liquid chromatography. 
from Boehringer Mannheim Gmbh. Spleen phosphodiesterase was 
from Worthington and Escherichia coli alkaline phosphatase was 
from Sigma. 
Cells and Virus-Cells were grown at 37 "C in RPMI 1640 medium 
(GIBCO)  containing 100 pg/ml of Kanamycin  supplemented  with  5% 
horse serum and 5% fetal calf serum for HeLa SB and Vero cells, 
respectively. HSV-1  (strain KOS) was maintained as described pre- 
viously (4). 
Preparation of HSV-I Thymidine  Kinase and  Human Erythrocyte 
Lysate-A highly purified enzyme was prepared from HSV-1-infected 
HeLa BU (TK-) cells using affinity column as described previously 
(5). Twenty-five ml of fresh heparinized blood was diluted with 
phosphate-buffered  saline (0.14 M NaC1, 4 mM KCI, 0.94 mM 
Na2HP0,, 0.15 M KH2P0,). Erythrocytes were pelleted by centrifu- 
gation and 4 volumes of cold water were added to lyse the cells. After 
centrifugation at  12,000 X g for 20 min, supernatant was collected 
and solid ammonium  sulfate was added to 70% saturation.  Precipitate 
was collected by centrifugation, dissolved in 10 ml of 5 mM Tris-HC1 
(pH 7.5), 2 mM dithiothreitol, 10% glycerol, and used for phospho- 
rylation of DHPGMP. 
Preparation ofdcid-soluble and -insoluble Fractions-HeLa S, cells 
in 25-cm2 flasks were infected with 3 plaque-forming units/cell of 
HSV-1. Various concentrations of [3H]DHPG were added at 0 h 
postinfection and  the cells were harvested at  6 h and washed three 
times with  phosphate-buffered  saline. The cell pellets (5 X lo6 cells) 
were extracted with 50 r l  of 1.5 M perchloric acid at  0 "C for 30 min. 
The extract was neutralized with 1 N potassium hydroxide (77 pl) 
and 23 p1 of 0.5 M potassium phosphate buffer (pH 7.4) was added. 
Precipitate was removed by centrifugation and  the  supernatant was 
used as  the acid-soluble fraction. The precipitate from the perchloric 
acid extraction were washed twice with 1.5 N perchloric acid and 
designated as  the acid-insoluble  fraction. 
Alkaline Hydrolysis ofdcid-insoluble Fractions-The acid-insoluble 
fraction was dissolved in 100 pl  of 1 N NaOH and incubated for 2 h 
at  37 "C. Four  hundred pl of 5% trichloroacetic acid was added to  the 
solution. The  supernatant  and  an additional 200-pl wash of trichlo- 
roacetic acid were neutralized  with KOH solution and counted in a 
liquid scintillation counter as the alkali-labile fraction. The pellet 
was redissolved in dimethyl sulfoxide and counted as  the alkali-stable 
material. 
HPLC Analysis-An anion exchange  column, Partisil 10 SAX/25 
(Whatman), was used in a  solvent  system  with a gradient of potassium 
phosphate buffer (pH 6.6) from 0.03 to 0.15 M. The solvent  system 
for a reverse phase  column, CS (ALLTECH), was acetonitrile, 0.03 M 
acetic acid (1-5000, v/v). 
Sodium Iodide and Cesium Sulfate Density Gradient Centrifuen- 
tion-HSV-1-infected cells were .washed with phosphate-buffered 
saline and lysed with  10 mM Tris-HC1 (pH 7.6), 1 mM EDTA, 0.1 M 
NaC1, 0.5% Sarkosyl, 0.5% sodium dodecyl sulfate (250 to 300 p l ) .  
After 30 min at  room temperature, proteinase K was added to  the 
lysate (6 mg/ml) and  the mixture was incubated  overnight at  37 "C. 
(4.7 ml) which contained 10 mM Tris-HC1 (pH 7.9), 10 mM EDTA, 
The mixture (300 pl) was directly layered on sodium iodide solution 
0.5 mg/ml of NaHSO,, and 1.53 to 1.54 g/cm3 of sodium iodide. 
Centrifugation was performed at  43,000 rpm for 48 h at 20 "C using 
a  Beckman SW 50.1 rotor. 
For cesium sulfate density  gradient  centrifugation, the mixture was 
extracted with '/z volume of phenol and  the aqueous phase was further 
extracted with ether.  One-tenth volume of 3 M sodium acetate buffer 
(pH 5.5) and 2.5 volume of ethanol were added to  the aqueous phase 
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and the mixture was kept at -80 “C for 1 h. The precipitate was 
dissolved in 10 mM Tris-HC1 (pH 7.4), 1 mM EDTA and cesium 
sulfate was  added to the solution  to a density of 1.53 g/cm3. Centrif- 
ugation  was at 25,000 rpm for 60 h using the same  rotor  as  above. 
Gradient solution was fractionated from top to bottom with a 
Buchler  Auto-Densi  Flow pump-dripper.  Density was  calculated  from 
refractive  index  measured  with  an  American  Optical ABBE refrac- 
tometer. 
RESULTS 
Uptake of DHPG  in Virus-infected and Mock-infected HeLa 
Cells-HeLa cells were infected with HSV-1 and various 
amounts of [‘HIDHPG were added at  0 h post-virus  adsorp- 
tion.  The cells were harvested at  6 h post-virus  adsorption. 
The uptake of DHPG into an acid-soluble and -insoluble 
fraction of these cells was analyzed. The  results  are  presented 
in Table I. The more DHPG added, the more uptake into 
both  fractions was  observed, with  the majority of [3H]DHPG 
uptake  taking place in  the acid-soluble fraction.  When 5 p~ 
DHPG was added to mock-infected HeLa cells, the  uptake of 
DHPG  into  the acid-soluble fraction was similar  to  that in 
infected cells  exposed to 0.5 KM DHPG.  The  uptake of DHPG 
into  the acid-insoluble fraction was about  the  same  as  that of
infected cells  exposed to between 1.0 and 2.0 p~ DHPG.  More 
than  three-quarters of [‘HJDHPG in  the acid-insoluble frac- 
tion could be rendered acid-soluble following treatment with 
1 N KOH. 
HPLC Analysis of DHPG Metabolites in Acid-soluble Frac- 
tion-The acid-soluble fraction of virus-infected  and mock- 
infected  HeLa cells after  the  treatment with  [‘HIDHPG was 
analyzed by HPLC  using a Partisil  10  SAX column system. 
The  results  are  shown  in F g. 1. In  addition  to  the radioactivity 
associated  with  the  DHPG  marker  fraction  (Fraction 5 ) ,  three 
other metabolites of DHPG were found in either virus-in- 
fected or mock-infected cells. One of the  metabolites  (Fraction 
20) was co-eluted  with a DHPGMP  marker.  The  amount of 
each metabolite formed in infected cells was dependent on 
the  extracellular  concentration of DHPG.  In  comparison with 
the virus-infected cells, very small amounts of metabolites 
could be found in the mock-infected cells and most of the 
radioactivity was in the DHPG fraction. When the extract 
from HSV-infected cells was treated  with  alkaline  phospha- 
tase for 4 h and  then analyzed with  the  same  HPLC  system, 
the radioactivity associated with each of these metabolites 
was decreased with a corresponding increase of radioactivity 
associated with the  DHPG  fraction (Fig. 1D). When  alkaline 
phosphatase-treated  sample was subjected to  the reverse 
phase Ce HPLC  column  system,  the  majority of the radioac- 
tivity was found to  be associated  with DHPG.’ 
In order to identify these three metabolites further, each 
compound was isolated by HPLC  and subjected to DEAE- 
Sephadex  column  chromatography in urea-containing buffer 
(Fig. 2). This allows the  separation of nucleotides based on 
the  number of ionic charges  on  phosphate groups. The  metab- 
olites associated with fractions 19 and 20 (Compound I), 25 
and 26 (Compound Z ) ,  and 52 to 55 (Compound 3) in Fig. 1 
eluted  slightly  faster  than  GMP,  GDP,  and  GTP, respectively. 
These results indicate that Compounds 1, 2, and 3 were 
mono-,  di-,  and  triphosphate derivatives of DHPG. 
I n  Vitro Formation of Metabolites-Highly purified HSV-1 
thymidine  kinase was incubated  with [’HIDHPG in  the  pres- 
ence of ATP.  The major metabolite formed co-eluted with 
DHPGMP on HPLC/Partisil 10 SAX system as shown in 
Fig. 3. [“HIDHPGMP was isolated  and  then  incubated with 
human  erythrocyte  lysate in the presence of ATP. As shown 
Y.-C. Cheng, S. P. Grill, G. E. Dutschman, K. Nakayama, and K. 
F. Bastow, unpublished observations. 
TABLE I 
Concentration-dependent  uptake of [’HJDHPG by HSV-infected 
HeLa S3 cells 
HeLa S3 cells were infected  with  HSV-1 (KOS) at 3 plaque-forming 
units/cells. [3H]DHPG (1.6 X lo3 cpm/pmol)  was  added at 0 h 
postinfection. Cells were harvested 6 h postinfection. Alkali-labile 
and  alkali  stable  acid-insoluble  radioactivity was determined  as  de- 




W prnol/l@ cells 
0.5 2.63 0.08 0.03 
1 5.10 0.16 0.05 
2 7.70 0.36 0.08 
5 17.0 0.80 0.20 
5“ 2.19 0.24 0.03 
Uninfected  HeLa St cells. 
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FIG. 1. HPLC analysis of DHPG metabolites in HSV-in- 
fected and mock-infected HeLa cells. Acid-soluble  fraction was 
prepared  from  HSV-infected  cells  treated  with 0.5 ( A ) ,  1 (E), 2 ( C ) ,  
and 5 (D) SM [’HIDHPG and from uninfected cells treated with 5 
SM [3H]DHPG (E)  and applied on a Partisil 10 SAX column as 
described  under “Materials and  Methods.” Acid extract from  HSV- 
infected cells treated with 5 SM L3H]DHPG was incubated with 
alkaline  phosphatase for 4 h at 37 “C and analyzed (D,o). The  radio- 
specificity of [3H]DHPG used was 1.6 X lo3 cpm/pmol. The sample 
injected  was  equivalent to the amount  extracted from 5 X IO5 cells. 
in Fig. 4, it was converted  to  metabolites which gave the  same 
retention  times  as  those of in vivo metabolites, Compounds 2 
and 3, respectively. This conversion was inhibited by GMP, 
but  not by TMP,  UMP, or AMP,2 suggesting that  the enzyme 
responsible for  the conversion of DHPGMP  to  DHPGDP is 
GMP kinase. The decrease of Compound 2 and  the increase 
of Compound 3 with  longer incubation suggested that Com- 
pound 2 is  the  precursor of Compound 3 (Fig. 3, B and C). 
Incorporation of DHPG into DNA-HSV-1-infected cells 
were treated  with 2 p~ [‘HIDHPG for 8 h and  the cell lysate 
was subjected to sodium iodide density  gradient  centrifuga- 
tion. Although this  method allows separation of virus DNA 
(density = 1.52) from host cell DNA (density 1.50), they 
were not  distinguishable for  [‘HIDHPG-labeled DNA, which 
distributed  into  the  fractions between the two densities (Fig. 
5A). 
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FIG.  2. DEAE-Sephadex column chromatography of [3H] 
DHPG metabolites. An aliquot of Compound 1 (A) ,  2 ( B ) ,  or 3 (C) 
(as designated in the  text), together with 100 nmol each of GMP, 
GDP,  and  GTP, were applied  on  a  DEAE-Sephadex column (0.3 X 
25 cm)  equilibrated  with 20 mM Tris-HC1 (pH 7.5), 1 mM EDTA,  7 
M urea. Elution was performed  with  a NaCl gradient (30 ml) from 0 
to 150 mM in the same buffer as above. One-ml fractions were 
collected. After absorbance at  260 nm was measured to locate the 
elution position of GMP,  GDP,  and  GTP (arrows), each  fraction was 
mixed with 10 ml of ACS scintillant (Amersham) and counted in a 
liquid scintillation counter  to  determine  the elution of the  [3H]DHPG 
metabolites. 
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FIG. 3. In vitro phosphorylation of [3H]DHPG with HSV-1 
thymidine kinase. [3H]DHPG (0.26 pCi, 7.3 nmol) was incubated 
at 37 “C in a  mixture (100 pl) containing 4.0 mg/ml of bovine serum 
albumin, 12.0 mg/ml of creatine phosphate, 0.4 mg/ml of creatine 
phosphokinase, 67 mM Tris-HC1 buffer (pH 7.5), 3 mM sodium 
fluoride, 0.6 mM dithiothreitol, 9 mM ATP”$+, and 4 units of HSV- 
1 thymidine kinase. Acid-soluble fractions at  0 h (A)  and 2 h ( B )  of 
incubation were analyzed by HPLC using Partisil 10 SAX as de- 
scribed under  “Materials  and Methods.” Elutions of standard  DHPG 
and  DHPGMP were indicated by arrows. 
It is quite possible that [‘HIDHPG-labeled DNA  has dif- 
ferent  density  from  normal DNA,  which makes  the  virus  and 
host DNA indistinguishable by density. 
When  these  fractions were treated  with  alkali, a portion of 
radioactivity became  acid-soluble and  the radioactivity in  the 
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FIG. 4. I n  vitro formation of di- and triphosphate deriva- 
tives from t3H]DHPGMP with human erythrocyte lysate. t H ]  
DHPGMP was prepared with HSV-1 thymidine  kinase and purified 
by HPLC as described in the legend to Fig. 3. Aliquots of [3H] 
DHPGMP were incubated  with  10 units of HSV-1 thymidine  kinase 
for 5 h ( A )  or 80 pl of human erythrocyte  lysate for 5  h ( B )  and 17 h 
(C) in  the reaction  mixtures described in the legend to Fig. 3. Reaction 
was terminated by the addition of perchloric acid and acid-soluble 
fraction was analyzed by HPLC using Partisil 10 SAX column as 
described under “Materials  and Methods.” 
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FIG. 5. Sodium iodide density gradient centrifugation by 
[3H]DHPG-labeled nucleic acid. HeLa SB cells in a 25-cm2 flask 
were infected  with HSV-1 and incubated in medium (2 ml) containing 
[3H]DHPG  (53 pCi, 9.3 nmol) for 8 h. Extraction of nucleic acid and 
centrifugation were as described under “Materials and Methods.” 
Seventy-five pl of each  fraction were collected. Twenty-five p1 of each 
fraction were absorbed into fiber glass discs (Whatman GF/A) and 
the discs were washed three times with ice-cold 5% trichloroacetic 
acid and once  with ethanol.  When dry, the discs were counted in ACS 
scintillant (A). Five p1 of 5 N NaOH was added to  another 25 pl of 
each fraction. The mixtures were incubated at  37 “C for 2 h, absorbed 
into discs, and washed as above (B) .  
alkali-stable form resulted in two peaks with densities 1.50 
and 1.52, respectively (Fig. 5B). 
Nucleic acid extracted from [”IDHPG-treated infected 
cells was analyzed by cesium sulfate  density  gradient  centrif- 
ugation. Most of the radioactivity  was  associated with  DNA 
(Fig. 6A). The radioactive  DNA  was  digested with micrococcal 
nuclease and  spleen  phosphodiesterase  and  the  products were 
analyzed  by HPLC/Partisil 10 SAX.  This  method allows us 
to  distinguish  terminally  incorporated nucleoside,  which gives 
nucleoside, from internally incorporated nucleoside, which 
gives nucleoside 3’-monophosphate. AS shown in Fig. 6B, 
there was little  DHPG produced, while a significant  amount 
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FIG. 6. Characterization of [3H]DHPG incorporated into 
DNA. A ,  cesium sulfate  density  gradient  centrifugation of [3H] 
DHPG-labeled nucleic acid. Incubation of HSV-infected cells with 
[3H]DHPG was performed as described in  the legend to Fig. 5 .  Other 
details are described under “Materials  and Methods.” One hundred 
sixty pl of each  fraction was collected and 15 gl each was counted for 
radioactivity. B, HPLC analysis of spleen  phosphodiesterase  digests 
of [3H]DHPG-labeled DNA. Fractions 3 and 4 from cesium sulfate 
gradient  centrifugation were combined and dialyzed against  10 mM 
Tris-HC1 (pH 7.4), 1 mM EDTA. DNA was precipitated with ethanol 
and dissolved in the above buffer (20  gl). After heat  denaturation, 
the labeled DNA was treated with 0.6 unit of micrococcal nuclease in 
a total volume of 50 gI (10 mM Tris-HC1, pH 8.8, 2 mM CaC1,) for 30 
min a t  37 “C. Added to  the mixture were 1 pl of 50 mM EDTA, 3 p1 
of 1 M sodium acetate buffer (pH 6.5), 3 gl of 0.1 M MgCI,, and 2.2 pl 
of 10 mg/ml spleen  phosphodiesterase (0.1 unit). Incubation was at 
37 “C for 60 min. Protein was precipitaed by the addition of 2 volumes 
(120 pl)  of 1 M perchloric acid. After centrifugation in a microfuge, 
supernatant was collected and neutralized with 4 M potassium hy- 
droxide  solution. Precipitate was removed by centrifugation and 
supernatant was lyophilized. The DNA digest was dissolved in water 
and an aliquot was applied on a Partisil 10 SAX column together 
with standard  DHPG  and  DHPGMP (arrows). 
of radioactivity was associated with DHPGMP and other 
material, which was possibly  dinucleotide resulting from in- 
complete digestion. These results indicate that DHPG was 
internally  incorporated  into DNA and  therefore does not  act 
as  pure  chain  terminator for DNA  synthesis. 
DISCUSSION 
Like several other selective anti-HSV nucleoside analogs 
(6-15), DHPG could  be preferentially  phosphorylated  in 
HSV-infected cells. The  primary metabolic scheme  is  shown 
in Fig. 7. In spite of two symmetrical -CH20H groups at 
carbon 2 of the propoxyl  group of DHPG,  the  phosphorylation 
of DHPG could take place at  one of those two -OH groups 
by virus-induced thymidine kinase. Two stereoisomers at 
carbon 2 could be anticipated.  It  is  probable  that only one 
stereoisomer of DHPGMP which could be utilized for the 
further  metabolism was  formed since all the  DHPGMP was 
converted to DHPGDP and DHPGTP by the erythrocyte 
lysate.  However, the possibility that  the  enzyme(s) responsi- 
ble for  further  phosphorylation could not  distinguish  the two 
stereoisomers requires further  experimentation. I t  seems 
likely that  the isomer  formed should have  a steric  conforma- 
tion  similar  to  dGMP,  but regardless of the outcome of this 
issue, the host cells apparently have an efficient system to 
carry out further phosphorylation as indicated in Fig. 1E. 
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FIG. 7. Possible metabolic pathways of DHPG. G and P rep- 
resent  guanine and  phosphate group, respectively. 
cells, although DHPG could be found in the acid-insoluble 
fraction.  This implies that a cell enzyme could perform  the 
initial  phosphorylation of DHPG  but  in a relatively  inefficient 
manner  since  other  human herpesviruses are less  susceptible 
to DHPG  than  HSV  and  these viruses do  not  induce virus- 
specific thymidine  kinase (1-3). The  host enzymes  responsible 
for the  phosphorylation of DHPGMP  to  DHPGDP could be 
GMP  kinases  since  GMP could inhibit  this process.  A similar 
suggestion was also made recently (16). Although there are 
several GMP kinase isozymes (17), it is not clear whether 
there is a preference for a particular  GMP  kinase isozyme in 
this process. 
The amount of accumulated DHPGTP in infected cells 
treated  with  DHPG  at  concentrations of 0.5, 1, 2, and 5 FM 
was 0.5, 1.2, 2.8, and 8.4 pmol/106 cells, respectively. The 
amount of DHPG  incorporated  into  the acid-insoluble frac- 
tion was found to be less than 5-propyl-dUrd (13). This 
suggested the posssibility that DHPG is acting as a chain 
terminator  such  as acyclovir or possibly a pseudochain ter- 
minator  such  as  arabinosyl  adenine  (19). A  detailed study of 
the mode of DHPG (18) on virus DNA replication is in 
progress. Since a portion of DHPG  incorporated  into  the acid- 
insoluble fraction  is alkali-labile, the possibility is raised that 
either  DHPG could be incorporated  into RNA  which is  alka- 
line-labile or into DNA with  an  alkali-labile linkage. Using 
the CszSOs  isopycnic centrifugation  technique, all the  radio- 
activity of [3H]DHPG  in  the nucleic acid from  the  infected 
cells was found to be with DNA. DHPG was also demon- 
strated  to be incorporated  into  the  internucleotide  chain of 
DNA. The unpublished  results of this  laboratory  using  an in 
uitro DNA  synthesis  system catalyzed by HSV DNA  polym- 
erase  further  confirms  the  incorporation of DHPG  into  the 
internucleotide  chain of DNA. The  alkaline lability of DHPG 
in the  internucleotide  DNA  chain or at  the  terminal of DNA 
is  currently  under  investigation. 
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